Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Maximizing Success: A Comprehensive Guide to Consulting for Medical Device Development in California

Jul 30, 2025

Understanding the Medical Device Landscape in California

California is a hub for innovation in the medical device industry, boasting a thriving ecosystem of startups, established companies, and research institutions. The state's unique blend of technology and healthcare expertise makes it an ideal location for developing groundbreaking medical devices. However, navigating this complex landscape requires strategic planning and specialized knowledge.

The medical device industry in California is subject to stringent regulations and standards. Consulting with experts who understand these requirements is crucial to ensuring compliance and facilitating product development. Companies must be well-versed in both state and federal guidelines to successfully bring their products to market.

medical device development

The Role of Consulting in Product Development

Consultants play a vital role in guiding medical device companies through the intricate stages of product development. From concept to commercialization, consultants provide valuable insights and expertise that can significantly impact a project's success. Their involvement can help streamline processes, reduce costs, and mitigate risks.

One of the primary benefits of consulting is the ability to leverage external expertise. Consultants often have extensive experience in specific areas, such as regulatory affairs, quality assurance, or clinical trials. This specialized knowledge can be instrumental in overcoming challenges and accelerating development timelines.

Key Areas of Consulting Support

Consulting services can encompass various aspects of medical device development. Some key areas where consultants can provide support include:

  • Regulatory compliance: Ensuring adherence to FDA regulations and state-specific requirements.
  • Quality management: Implementing robust quality systems to maintain high standards.
  • Clinical trial management: Designing and executing clinical studies to validate product efficacy and safety.
consulting meeting

Strategies for Choosing the Right Consultant

Selecting the right consultant is critical to maximizing success in medical device development. Companies should consider several factors when evaluating potential partners, such as their track record, expertise, and alignment with the company's goals. Conducting thorough due diligence is essential to identify consultants who can truly add value to the project.

Engaging with consultants who have a proven history of successful collaborations in the medical device sector can provide a competitive edge. These experts often bring a wealth of industry connections and insights that can facilitate smoother interactions with regulatory bodies and other key stakeholders.

Establishing Effective Collaboration

An effective partnership between a company and its consultant requires clear communication and mutual understanding. Establishing well-defined objectives, timelines, and deliverables at the outset can help ensure both parties are aligned and working towards common goals. Regular updates and feedback cycles are also crucial for maintaining momentum and addressing any emerging issues promptly.

team collaboration

Maximizing Success Through Continuous Improvement

Continuous improvement is a fundamental principle for achieving long-term success in medical device development. By incorporating feedback from consultants and other stakeholders, companies can refine their strategies and processes over time. This iterative approach allows for adaptability and responsiveness to changing market conditions and regulatory landscapes.

Ultimately, the key to maximizing success in consulting for medical device development lies in building strong, collaborative relationships. By leveraging expert guidance and maintaining a commitment to excellence, companies can navigate the complexities of the industry and deliver innovative solutions that improve patient outcomes.